Recurrent or Metastatic Head and Neck Cancer Pipeline Analysis Report 2025

According to the Global Cancer Statistics of 2020, head and neck cancer ranked as the third most prevalent cancer globally. Head and neck cancer accounts for approximately 71,100 cases and 16,100 deaths annually in the United States. Head and neck cancer refers to several types of cancers which affect the mouth, throat, and other parts of the head and neck. Common symptoms include persistent sore throat. Companies are innovating more effective and tolerable targeted therapies to improve the outcomes for patients with head and neck cancer. Recent clinical trials have focused on identifying promising biomarkers and developing more effective targeted therapies.

Report Coverage

The Recurrent or Metastatic Head and Neck Cancer Drug Pipeline Report by the publisher gives comprehensive insights into recurrent or metastatic head and neck cancer drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for recurrent or metastatic head and neck cancer. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from recurrent or metastatic head and neck cancer.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to recurrent or metastatic head and neck cancer are covered.

Recurrent or Metastatic Head and Neck Cancer Drug Pipeline Outlook

Head and neck cancer includes various types of cancer which usually start in the cells lining mouth, throat, or larynx. These cells are called squamous cells. Though less common, head and neck cancers form in sinuses or salivary glands as well. Most of the head and neck cancers are classified as squamous cell carcinoma after the cell which changes into cancer cell. Head and neck cancers include oral cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, nasopharyngeal cancer, and salivary gland cancer among others. Head and neck cancer is difficult to diagnose because symptoms are mild and can mimic less serious conditions like a cold or sore throat. The symptoms include persistent sore throat, pain in upper teeth, frequent headaches, voice changes and facial numbness or pain among others.

The treatment for head and neck cancer varies depending on the stage and type of cancer. It mainly involves surgery, radiation therapy and chemotherapy, targeted therapy, and immunotherapy. Targeted therapy is mostly given in combination with other treatments to treat advanced head and neck cancers. Cetuximab (Erbitux®) is a drug which targets a tumor protein called epidermal growth factor and is approved by the U.S. FDA to treat head and neck cancers. Currently clinical trials on head and neck cancer treatments are evaluating new immunotherapy drugs and radiation therapy techniques. Clinical trials are also focused on identifying promising biomarkers and developing more effective targeted therapies.

Recurrent or Metastatic Head and Neck Cancer - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of recurrent or metastatic head and neck cancer drugs based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The pipeline assessment report covers 50+ drug analyses based on drug classes:

• Small Molecule
• Cell Therapy
• Peptides
• Polymer
• Gene Therapy

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Recurrent or Metastatic Head and Neck Cancer - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for recurrent or metastatic head and neck cancer with 410 pipeline drugs in the respective phase.

Recurrent or Metastatic Head and Neck Cancer - Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under recurrent or metastatic head and neck cancer pipeline analysis include cell therapy, peptides, polymer, small molecule, and gene therapy. Immune therapies are the most recent advancements in the field of head and neck cancer. It boosts the patient’s immune system to fight the spreading of tumors. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for recurrent or metastatic head and neck cancer.

Recurrent or Metastatic Head and Neck Cancer Clinical Trials Assessment - Competitive Dynamics

The report for the recurrent or metastatic head and neck cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in recurrent or metastatic head and neck cancer clinical trials:

• Sanofi
• Bristol-Myers Squibb
• Eli Lilly and Company
• Pierre Fabre Medicament
• Trisha Wise-Draper
• Pfizer
• Nektar Therapeutics
• Coordination Pharmaceuticals, Inc.
• Amgen
• Dynavax Technologies Corporation
• Merck Sharp & Dohme LLC
• Innate Pharma
• Ikena Oncology
• Others

Recurrent or Metastatic Head and Neck Cancer - Pipeline Drugs Profile

Drug: Pemetrexed

The trial is designed to investigate the improvement in progression-free survival with the combination of pemetrexed, carboplatin and cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The trial is sponsored by Eli Lilly and Company and is currently under phase II.

Drug: PF-00299804

Pfizer is developing the drug and is currently under phase II. The study is being designed to evaluate the safety and efficacy of oral PF-00299804 in patients with recurrent and/ or metastatic head and neck squamous cell cancer.

Reasons To Buy This Report

The Recurrent or Metastatic Head and Neck Cancer Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for recurrent or metastatic head and neck cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within recurrent or metastatic head and neck cancer pipeline insights.

Key Questions Answered in the Recurrent or Metastatic Head and Neck Cancer - Pipeline Assessment Report

• What is the current landscape of recurrent or metastatic head and neck cancer pipeline drugs?
• How many companies are developing recurrent or metastatic head and neck cancer drugs?
• How many phase III and phase IV drugs are currently present in recurrent or metastatic head and neck cancer pipeline drugs?
• Which companies/institutions are leading the recurrent or metastatic head and neck cancer drug development?
• What is the efficacy and safety profile of recurrent or metastatic head and neck cancer pipeline drugs?
• What are the opportunities and challenges present in the recurrent or metastatic head and neck cancer drug pipeline landscape?
• Which company is conducting major trials for recurrent or metastatic head and neck cancer drugs?
• What are the geographies covered for clinical trials in recurrent or metastatic head and neck cancer?
• What are emerging trends in recurrent or metastatic head and neck cancer clinical trials?

This product will be delivered within 3-5 business days.